Evidence map›Paper›PMID 26714410›Full record

ReviewTissue engineering. Part B, Reviews2016

Tissue Engineering and Regenerative Medicine 2015: A Year in Review.

Holly Wobma, Gordana Vunjak-Novakovic

Abstract readReview
In one paragraph

Review in Tissue engineering. Part B, Reviews, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Decellularization Methods of Uterus in Tissue Engineering.Advances in experimental medicine and biology · 2021
    Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Holly Wobma1 Department of Biomedical Engineering, Columbia University , New York.
Gordana Vunjak-Novakovic1 Department of Biomedical Engineering, Columbia University , New York.

Funding

Translational Bioreactors - Engineering Complex TissuesP41EB002520 · NIBIB · TUFTS UNIVERSITY MEDFORD · PI KAPLAN, DAVID L. · 2004 to 2018
$16.7M
Engineering Vascularized Cardiac MuscleR01HL076485 · NHLBI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Gordana Vunjak-Novakovic · 2005 to 2026
$9.2M
Tissue Chips for Rare Disease: Adding Timothy Syndrome to the HeLIVaSkCa platformUH3EB017103 · NIBIB · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI VUNJAK-NOVAKOVIC, GORDANA · 2014 to 2016
$7.1M
Bioengineering a Chimeric Human LungR01HL120046 · NHLBI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI SNOECK, HANS-WILLEM E, VUNJAK-NOVAKOVIC, GORDANA · 2013 to 2022
$6.1M
Craniofacial Tissue EngineeringR01DE016525 · NIDCR · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI VUNJAK-NOVAKOVIC, GORDANA · 2005 to 2017
$5.5M
Electrotherapeutic strategies for connective tissue repairR01AR061988 · NIAMS · TUFTS UNIVERSITY MEDFORD · PI HUNG, CLARK T., KAPLAN, DAVID L. · 2011 to 2015
$3.3M
NHLBI NIH HHS R01 HL076485NHLBI NIH HHS R01 HL120046NIAMS NIH HHS R01 AR061988NIBIB NIH HHS P41 EB002520NIBIB NIH HHS UH3 EB017103NIDCR NIH HHS R01 DE016525
6 · The paper itself

Abstract

This may be the most exciting time ever for the field of tissue engineering and regenerative medicine (TERM). After decades of progress, it has matured, integrated, and diversified into entirely new areas, and it is starting to make the pivotal shift toward translation. The most exciting science and applications continue to emerge at the boundaries of disciplines, through increasingly effective interactions between stem cell biologists, bioengineers, clinicians, and the commercial sector. In this "Year in Review," we highlight some of the major advances reported over the last year (Summer 2014-Fall 2015). Using a methodology similar to that established in previous years, we identified four areas that generated major progress in the field: (i) pluripotent stem cells, (ii) microtissue platforms for drug testing and disease modeling, (iii) tissue models of cancer, and (iv) whole organ engineering. For each area, we used some of the most impactful articles to illustrate the important concepts and results that advanced the state of the art of TERM. We conclude with reflections on emerging areas and perspectives for future development in the field.

Indexed as

Drug Evaluation, PreclinicalHumansModels, BiologicalNeoplasmsPluripotent Stem CellsRegenerative MedicineTissue Engineering

Identifiers

PMID26714410
PMCPMC4817587

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.